REPLIGEN CORP (RGEN) Stock Fundamental Analysis
NASDAQ:RGEN - Nasdaq - US7599161095 - Common Stock - Currency: USD
Taking everything into account, RGEN scores 5 out of 10 in our fundamental rating. RGEN was compared to 55 industry peers in the Life Sciences Tools & Services industry. While RGEN has a great health rating, its profitability is only average at the moment. RGEN is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year RGEN was profitable.
In the past year RGEN had a positive cash flow from operations.
Of the past 5 years RGEN 4 years were profitable.
Each year in the past 5 years RGEN had a positive operating cash flow.
1.2 Ratios
RGEN has a better Return On Assets (-0.69%) than 63.64% of its industry peers.
RGEN's Return On Equity of -0.99% is fine compared to the rest of the industry. RGEN outperforms 67.27% of its industry peers.
RGEN's Return On Invested Capital of 0.48% is in line compared to the rest of the industry. RGEN outperforms 60.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for RGEN is significantly below the industry average of 13.60%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.69% | ||
| ROE | -0.99% | ||
| ROIC | 0.48% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
RGEN's Operating Margin of 2.56% is in line compared to the rest of the industry. RGEN outperforms 60.00% of its industry peers.
RGEN's Operating Margin has declined in the last couple of years.
RGEN has a Gross Margin (51.03%) which is in line with its industry peers.
In the last couple of years the Gross Margin of RGEN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.56% | ||
| PM (TTM) | N/A | ||
| GM | 51.03% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RGEN is destroying value.
RGEN has more shares outstanding than it did 1 year ago.
RGEN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, RGEN has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.84 indicates that RGEN is not in any danger for bankruptcy at the moment.
RGEN has a Altman-Z score of 5.84. This is amongst the best in the industry. RGEN outperforms 87.27% of its industry peers.
The Debt to FCF ratio of RGEN is 4.42, which is a neutral value as it means it would take RGEN, 4.42 years of fcf income to pay off all of its debts.
RGEN's Debt to FCF ratio of 4.42 is fine compared to the rest of the industry. RGEN outperforms 69.09% of its industry peers.
A Debt/Equity ratio of 0.27 indicates that RGEN is not too dependend on debt financing.
RGEN has a Debt to Equity ratio (0.27) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.42 | ||
| Altman-Z | 5.84 |
ROIC/WACC0.05
WACC9.47%
2.3 Liquidity
RGEN has a Current Ratio of 6.79. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
RGEN has a better Current ratio (6.79) than 87.27% of its industry peers.
A Quick Ratio of 5.79 indicates that RGEN has no problem at all paying its short term obligations.
RGEN's Quick ratio of 5.79 is amongst the best of the industry. RGEN outperforms 85.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.79 | ||
| Quick Ratio | 5.79 |
3. Growth
3.1 Past
RGEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.06%, which is quite good.
Measured over the past 5 years, RGEN shows a small growth in Earnings Per Share. The EPS has been growing by 7.11% on average per year.
Looking at the last year, RGEN shows a very strong growth in Revenue. The Revenue has grown by 32.28%.
Measured over the past years, RGEN shows a quite strong growth in Revenue. The Revenue has been growing by 18.62% on average per year.
EPS 1Y (TTM)16.06%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%39.29%
Revenue 1Y (TTM)32.28%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%11.8%
3.2 Future
The Earnings Per Share is expected to grow by 25.08% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 15.37% on average over the next years. This is quite good.
EPS Next Y15.7%
EPS Next 2Y21.77%
EPS Next 3Y23.52%
EPS Next 5Y25.08%
Revenue Next Year11.75%
Revenue Next 2Y13.04%
Revenue Next 3Y13.99%
Revenue Next 5Y15.37%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 80.17 indicates a quite expensive valuation of RGEN.
The rest of the industry has a similar Price/Earnings ratio as RGEN.
When comparing the Price/Earnings ratio of RGEN to the average of the S&P500 Index (27.45), we can say RGEN is valued expensively.
With a Price/Forward Earnings ratio of 58.09, RGEN can be considered very expensive at the moment.
The rest of the industry has a similar Price/Forward Earnings ratio as RGEN.
RGEN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.90.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 80.17 | ||
| Fwd PE | 58.09 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as RGEN.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of RGEN is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 59.81 | ||
| EV/EBITDA | 61.58 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RGEN does not grow enough to justify the current Price/Earnings ratio.
RGEN's earnings are expected to grow with 23.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)5.11
PEG (5Y)11.28
EPS Next 2Y21.77%
EPS Next 3Y23.52%
5. Dividend
5.1 Amount
RGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
127.47
+0.51 (+0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.63%
Inst Owner Change2.88%
Ins Owners0.51%
Ins Owner Change-0.5%
Market Cap7.16B
Analysts80
Price Target187.27 (46.91%)
Short Float %6.47%
Short Ratio4.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.97%
Min EPS beat(2)5.21%
Max EPS beat(2)10.73%
EPS beat(4)3
Avg EPS beat(4)10.26%
Min EPS beat(4)-0.8%
Max EPS beat(4)25.89%
EPS beat(8)5
Avg EPS beat(8)9.59%
EPS beat(12)9
Avg EPS beat(12)11.22%
EPS beat(16)13
Avg EPS beat(16)15.65%
Revenue beat(2)1
Avg Revenue beat(2)-0.4%
Min Revenue beat(2)-2.03%
Max Revenue beat(2)1.23%
Revenue beat(4)1
Avg Revenue beat(4)-0.93%
Min Revenue beat(4)-2.03%
Max Revenue beat(4)1.23%
Revenue beat(8)1
Avg Revenue beat(8)-1.77%
Revenue beat(12)3
Avg Revenue beat(12)-0.5%
Revenue beat(16)7
Avg Revenue beat(16)1.4%
PT rev (1m)0%
PT rev (3m)-3.02%
EPS NQ rev (1m)1.38%
EPS NQ rev (3m)-5.89%
EPS NY rev (1m)0.21%
EPS NY rev (3m)-1.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.88%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.71%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 80.17 | ||
| Fwd PE | 58.09 | ||
| P/S | 8.91 | ||
| P/FCF | 59.81 | ||
| P/OCF | 49.15 | ||
| P/B | 3.61 | ||
| P/tB | 14.5 | ||
| EV/EBITDA | 61.58 |
EPS(TTM)1.59
EY1.25%
EPS(NY)2.19
Fwd EY1.72%
FCF(TTM)2.13
FCFY1.67%
OCF(TTM)2.59
OCFY2.03%
SpS14.3
BVpS35.34
TBVpS8.79
PEG (NY)5.11
PEG (5Y)11.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.69% | ||
| ROE | -0.99% | ||
| ROCE | 0.76% | ||
| ROIC | 0.48% | ||
| ROICexc | 0.65% | ||
| ROICexgc | 2.53% | ||
| OM | 2.56% | ||
| PM (TTM) | N/A | ||
| GM | 51.03% | ||
| FCFM | 14.9% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
ROICexc(3y)3.74%
ROICexc(5y)4.93%
ROICexgc(3y)17.96%
ROICexgc(5y)N/A
ROCE(3y)4.23%
ROCE(5y)5.26%
ROICexcg growth 3Y-71.22%
ROICexcg growth 5Y-37.94%
ROICexc growth 3Y-63.64%
ROICexc growth 5Y-32.38%
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
F-Score5
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.42 | ||
| Debt/EBITDA | 4.66 | ||
| Cap/Depr | 27.92% | ||
| Cap/Sales | 3.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 128.29% | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.79 | ||
| Quick Ratio | 5.79 | ||
| Altman-Z | 5.84 |
F-Score5
WACC9.47%
ROIC/WACC0.05
Cap/Depr(3y)88.31%
Cap/Depr(5y)109.53%
Cap/Sales(3y)7.3%
Cap/Sales(5y)7.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.06%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%39.29%
EPS Next Y15.7%
EPS Next 2Y21.77%
EPS Next 3Y23.52%
EPS Next 5Y25.08%
Revenue 1Y (TTM)32.28%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%11.8%
Revenue Next Year11.75%
Revenue Next 2Y13.04%
Revenue Next 3Y13.99%
Revenue Next 5Y15.37%
EBIT growth 1Y739.35%
EBIT growth 3Y-59.22%
EBIT growth 5Y-19.7%
EBIT Next Year68.28%
EBIT Next 3Y40.73%
EBIT Next 5Y36.8%
FCF growth 1Y32.01%
FCF growth 3Y45.03%
FCF growth 5Y27.02%
OCF growth 1Y-9.06%
OCF growth 3Y13.8%
OCF growth 5Y21.15%